Catalog No.
Product Name
Application
Product Information
Citations
-
mAChR Inhibitor
Tematropium is a selective muscarinic acetylcholine receptor (mAChR) inhibitor known for its soft anticholinergic properties. It demonstrates significant biological activity in modulating bronchoconstriction and respiratory secretions. Tematropium is commonly used in research focused on respiratory diseases, exploring its potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD). -
mAChR Modulator
BTM-1086 is a potent muscarinic acetylcholine receptor (mAChR) modulator, primarily functioning as an anti-ulcer agent. It demonstrates significant inhibitory activity against gastric secretion, making it valuable for research in gastrointestinal disorders. BTM-1086 can be utilized in studies focused on receptor signaling and the pharmacological management of gastric-related conditions. -
mAChR Antagonist
YM-46303 is an antagonist of muscarinic acetylcholine receptors (mAChR), demonstrating high affinity for both M1 and M3 subtypes, with notable selectivity for the M3 receptor over the M2 receptor. This compound is valuable in the study of receptor signaling pathways and can be utilized in research involving neurological disorders, smooth muscle contraction, and other cholinergic system-related investigations. Its specificity makes it a useful tool for elucidating the roles of mAChR subtypes in various biological processes. -
mAChR Inhibitor
Timepidium bromide is a muscarinic acetylcholine receptor (mAChR) inhibitor that exhibits anticholinergic properties. It is primarily utilized in research investigating acetylcholine signaling pathways and the role of mAChR in various physiological and pathological processes. This compound is valuable for studying conditions influenced by cholinergic activity, including respiratory and gastrointestinal disorders. -
mAChR Activator
Vinconate is an indolonaphthyridine derivative that acts as an activator of the muscarinic acetylcholine receptor (mAChR). This compound is utilized in research to investigate cholinergic signaling pathways and their implications in neurological and cognitive functions. Its ability to modulate mAChR activity makes it a valuable tool for exploring potential therapeutic applications in neurodegenerative diseases and cognitive disorders. -
mGluR1/CaMKIIα Activator
FO-4-15 is an mGluR1/CaMKIIα activator that demonstrates neuroprotective effects against oxidative stress, specifically H2O2, in human neuroblastoma SH-SY5Y cells. This compound enhances cognitive function in mouse models of Alzheimer’s disease by engaging the mGluR1/CaMKIIα signaling pathway, leading to a reduction in amyloid-beta accumulation, hyperphosphorylated Tau, and synaptic damage. It serves as a valuable tool for investigating mechanisms of neuroprotection and cognitive impairment in neurodegenerative diseases. -
NMDA Agonist
Cis-ACPD is a potent agonist of the NMDA receptor, exhibiting an IC50 of 3.3 µM. Additionally, it selectively activates group II metabotropic glutamate receptors, with EC50 values of 13 µM for mGluR2 and 50 µM for mGluR4. The compound is widely used in neuropharmacological research to study excitatory neurotransmission and the role of glutamate receptors in various neurological disorders. -
LTD4/PAF Receptor Antagonist
CP-96021 is a potent antagonist of the leukotriene D4 (LTD4) receptor (Ki = 34 μM) and the platelet activating factor (PAF) receptor (Ki = 37 μM). This compound effectively targets two key inflammatory mediators, making it valuable in research on inflammation-related pathologies. With a high specificity profile, CP-96021 demonstrates negligible activity against various receptors, including dopamine, adenosine, and GABA receptors, suggesting minimal off-target effects. This reagent can be employed in studies investigating the pathogenesis of inflammatory diseases, such as asthma. -
PA2/5-LOX/COX Inhibitor
LY256548 is a potent inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and cyclooxygenase (COX), demonstrating significant anti-ischemic and anti-inflammatory properties. This compound effectively reduces leukotriene B4 production in response to A23187 stimulation. In preclinical models, LY256548 has shown efficacy in mitigating bone damage and paw swelling in rat models of Freund's complete adjuvant-induced arthritis (FCA), making it a valuable tool for research into inflammatory diseases and analgesic mechanisms. -
mAChR Antagonist
Atropine is a competitive antagonist of muscarinic acetylcholine receptors (mAChR), exhibiting IC50 values of 0.39 nM for human mAChR M4 and 0.71 nM for chicken mAChR M4. This compound effectively inhibits acetylcholine-induced relaxations in human pulmonary veins. Atropine is utilized in research focused on anti-myopia and the treatment of bradycardia. -
mAChR Agonist
Betovumeline hydrochloride is an agonist of muscarinic acetylcholine receptors (mAChRs), which play a critical role in various neurological functions. This compound is valuable for research into neurological disorders, facilitating the study of receptor activation and signaling pathways. Its ability to selectively engage mAChRs makes it a useful tool in pharmacological investigations and potential therapeutic applications. -
mAChR Superagonist
Iperoxo is a potent superagonist of muscarinic acetylcholine receptors (mAChR), effectively activating M1, M2, and M3 subtypes with pEC50 values of 9.87, 10.1, and 9.78, respectively. This compound is valuable for investigating activation-related conformational transitions in muscarinic receptors, particularly when labeled with tritium. Its strong receptor activity makes Iperoxo suitable for research in neurotransmission and receptor pharmacology. -
M1 Antagonist
VU 0255035 is a highly selective and competitive antagonist of the M1 muscarinic acetylcholine receptor (mAChR). It effectively inhibits M1 mAChR signaling, which contributes to the reduction of epileptic seizures and the modulation of neuronal membrane potential. This compound is valuable for research applications focused on central nervous system disorders, including epilepsy, Parkinson's disease, and dystonia. -
BChE/NMDA/mAChR Antagonist
Ethopropazine hydrochloride is a potent and selective inhibitor of butyrylcholinesterase (BChE) and acts as a non-selective antagonist at muscarinic acetylcholine receptors (mAChR) and N-methyl-D-aspartate receptors (NMDA). This compound exhibits anticholinergic, antihistamine, and antiadrenergic activities, making it valuable in studying its effects on neuropathic pain conditions such as thermal hyperalgesia. Ethopropazine hydrochloride is particularly relevant in research related to Parkinson's disease, providing insights into cholinergic system modulation and receptor interactions. -
mAChR Antagonist
Otenzepad is a selective, competitive antagonist of the M2 muscarinic acetylcholine receptor, exhibiting IC50 values of 640 nM in rabbit peripheral lung tissue and 386 nM in rat heart tissue. This compound plays a significant role in modulating cholinergic signaling and has applications in research focused on respiratory and cardiovascular physiology. Its use aids in the study of receptor-mediated pathways and potential therapeutic targets in related disorders. -
mAChR Agonist
Oxotremorine sesquifumarate is an agonist of muscarinic acetylcholine receptors (mAChRs), primarily activating the M2 subtype. This compound is instrumental in neurological research, facilitating the study of cholinergic signaling and its implications in various neurological disorders. Its ability to modulate M2 receptor activity makes it valuable for investigating the physiological and pathophysiological roles of these receptors in the nervous system. -
M1 mAChR Antagonist
Pirenzepine is a selective antagonist of the M1 muscarinic acetylcholine receptor (mAChR) with limited ability to cross the blood-brain barrier. This compound is primarily utilized for its ability to inhibit gastric acid secretion and alleviate muscle spasm, making it relevant in the study of peptic ulcers. Additionally, Pirenzepine exhibits anti-proliferative properties in various cancer cell lines, providing valuable insights for cancer research applications. -
mAChR Modulator
Aceclidine, a modulator of muscarinic acetylcholine receptors, primarily targets the M3 receptor while also acting as an M1 receptor agonist (EC50: 40 μM). This compound serves as a cycloplegic agent, surfactant, tonicity adjustor, and can enhance viscosity and provide antioxidant effects. It is applicable in research focusing on conditions such as refractive errors of the eye, xerostomia, Sjögren's syndrome, glaucoma, conjunctivitis, lacrimal gland disorders, and esotropia. -
M5 mAChR Antagonist
VU6019650 is a potent and selective orthosteric antagonist of the M5 muscarinic acetylcholine receptor (IC50 = 36 nM). This compound is being investigated for its potential in alleviating opioid use disorder by modulating the mesolimbic dopaminergic reward circuitry. VU6019650 effectively reduces neuronal firing rates in midbrain dopamine neurons of the ventral tegmental area in response to Oxotremorine M iodide, offering insights into its pharmacological application in neuropsychiatric research. -
Aβ Inhibitor
Fustin (3,7,3',4'-Tetrahydroxyflavanone) is a potent inhibitor of amyloid β (Aβ), demonstrating significant effects on neurochemical markers associated with Alzheimer's disease. It enhances acetylcholine (ACh) levels and stimulates choline acetyltransferase (ChAT) activity while decreasing acetylcholinesterase (AChE) activity and expression. Additionally, Fustin promotes the expression of muscarinic M1 receptor genes and enhances receptor binding activity. This compound is valuable for research in Alzheimer's disease and neurodegenerative processes involving Aβ toxicity. -
mAChR Antagonist
(Rac)-5-Hydroxymethyl Tolterodine is a mAChR antagonist with high affinity for M1, M2, M3, M4, and M5 receptors, exhibiting Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM, respectively. This active metabolite of Tolterodine is valuable for investigating the pathophysiology and treatment of overactive bladder conditions. Its selective inhibition of muscarinic acetylcholine receptors allows for exploration of therapeutic strategies targeting bladder hyperactivity. -
M1 mAChR Agonist
GSK1034702 is an allosteric agonist of the M1 muscarinic acetylcholine receptor (mAChR) with a pEC50 of 8.1 and the capability to cross the blood-brain barrier. It activates the Gq/11 protein-mediated signaling pathway, promoting neuronal firing and enhancing long-term potentiation (LTP) in the hippocampal CA1 region. This compound is valuable for investigating cognitive impairment mechanisms, including those related to Alzheimer's disease, and has demonstrated pro-cognitive effects in models of nicotine withdrawal cognitive dysfunction. Additionally, GSK1034702 may elicit certain side effects associated with peripheral M receptor activation, including gastrointestinal reactions. -
Diacylglycerol Lipase Inhibitor
RHC 80267 is a potent and selective inhibitor of diacylglycerol lipase (DAGL), exhibiting an IC50 of 4 μM in canine platelets. This compound is valuable for research applications focusing on the modulation of lipid signaling pathways, particularly in the context of acetylcholine-induced relaxation. Additionally, RHC 80267 demonstrates inhibitory effects on cholinesterase with an IC50 of 4 μM and also inhibits cyclooxygenase (COX) and the hydrolysis of phosphatidylcholine (PC), making it a versatile tool for exploring lipid metabolism and neuronal signaling. -
mAChR Antagonist
Fesoterodine L-mandelate is a competitive antagonist of muscarinic acetylcholine receptors (mAChR), demonstrating non-subtype selectivity with pKi values of 8.0, 7.7, 7.4, 7.3, and 7.5 for M1, M2, M3, M4, and M5 receptors, respectively. This orally active compound is primarily utilized in the treatment of overactive bladder (OAB). Its inhibition of mAChRs contributes to a reduction in bladder contractions, providing therapeutic benefits for managing urinary incontinence. -
mAChR Antagonist
Dipeptide diaminobutyroyl benzylamide diacetate functions as a muscarinic acetylcholine receptor (mAChR) antagonist. It induces muscle relaxation, making it relevant in studies related to skin aging and facial wrinkles, including crow's feet and periorbital creases. This compound can be utilized in research focused on dermatological applications and the physiological mechanisms underlying muscle tone regulation in the skin. -
M5 mAChR NAM
ML375 is a potent negative allosteric modulator (NAM) of the M5 muscarinic acetylcholine receptor. With IC50 values of 300 nM and 790 nM for human and rat M5 receptors respectively, ML375 exhibits high selectivity and significant brain penetration. Its ability to selectively inhibit M5 mAChR makes ML375 a valuable tool for research applications, particularly in studies exploring cholinergic signaling and neurological functions. -
mAChR Antagonist
Fesoterodine is a competitive antagonist of muscarinic acetylcholine receptors (mAChR), exhibiting pKi values of 8.0, 7.7, 7.4, 7.3, and 7.5 for the M1, M2, M3, M4, and M5 subtypes, respectively. This orally active compound is primarily utilized in the treatment of overactive bladder (OAB) conditions. Its broad receptor targeting allows for effective modulation of bladder function, making it a valuable tool in urological research and therapy development. -
Relative Configuration of VU6021625
rel-VU6021625, a derivative of VU6021625, serves as a potent and selective antagonist of the mAChR M4 receptor, exhibiting IC50 values of 0.44 nM for human M4 and 57 nM for rat M4. This compound demonstrates significant potential in neurological research, particularly in the study of disorders related to cholinergic signaling. Its use can aid in understanding mAChR M4 functions and therapeutic applications targeting this receptor. -
nAChR Desensitizer
Anagyrine is a quinolizidine alkaloid that acts as a desensitizer of nicotinic acetylcholine receptors (nAChR). It demonstrates binding affinity with IC50 values of 132 µM for muscarinic receptors and 2096 µM for nicotinic receptors, effectively modulating nAChR activity. This compound is utilized in research to study nAChR desensitization mechanisms and its implications in various neural and pharmacological contexts. -
mAChR Activator
VU0238441 is a positive allosteric modulator targeting pan muscarinic acetylcholine receptors (mAChRs), demonstrating EC50 values of 3.2 μM, 2.8 μM, 2.2 μM, 2.1 μM for M1, M2, M3, and M5, respectively, while maintaining minimal activity against M4 (>10 μM). This compound enhances the receptor activity in a pharmacologically relevant manner and is valuable for exploring the role of mAChRs in neurological and cognitive research. Its applications include drug discovery and the study of receptor signaling pathways associated with cholinergic systems. -
M5 mAChR PAM
ML380 is a selective positive allosteric modulator (PAM) targeting the M5 muscarinic acetylcholine receptor (mAChR) with EC50 values of 190 nM for human and 610 nM for rat receptors. It demonstrates moderate selectivity over the M1 and M3 mAChR subtypes. By enhancing the affinity of acetylcholine for the M5 mAChR, ML380 may play a significant role in research focused on neurological and cognitive functions, offering potential avenues for the study of related disorders. -
M4 Receptor Antagonist
PCS1055 dihydrochloride is a selective and competitive antagonist of the muscarinic M4 receptor, with an IC50 value of 18.1 nM and a Kd of 5.72 nM. This compound effectively inhibits the binding of the radioligand [3H]-NMS to the M4 receptor, displaying a Ki of 6.5 nM. PCS1055 dihydrochloride demonstrates over 100-fold selectivity against M1, M3, and M5 receptors, and 30-fold selectivity at the M2 receptor. Additionally, it serves as a potent acetylcholinesterase inhibitor, with IC50 values of 22 nM and 120 nM for electric eel and human AChE, respectively, highlighting its potential for various neurological research applications. -
mAChR M5 Orthosteric Antagonist
ML381 is a selective orthosteric antagonist of the mAChR M5 receptor, with an IC50 of 450 nM and a Ki value of 340 nM. This compound is known for its ability to penetrate the central nervous system, making it a valuable tool for investigating the role of mAChR M5 in neurological research. Due to its instability in rat plasma, ML381 is primarily utilized as a molecular probe for in vitro studies and electrophysiological applications. -
mAChR Antagonist
Ipratropium bromide hydrate is a muscarinic acetylcholine receptor (mAChR) antagonist, exhibiting IC50 values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. This compound effectively induces relaxation of smooth muscle, making it valuable for research applications in chronic obstructive pulmonary disease (COPD) and asthma. Its selective inhibition of mAChRs contributes to its therapeutic potential in respiratory disorders. -
mAChR Antagonist
Tiotropium bromide monohydrate is a long-acting antagonist of muscarinic acetylcholine receptors (mAChRs). It exhibits significant bronchodilator activity, making it effective in the management of chronic obstructive pulmonary disease (COPD) and asthma. This compound is widely utilized in research studies investigating respiratory pharmacology and cholinergic signaling pathways. -
M4 mAChR Antagonist
VU6028418 is a potent and highly selective antagonist of the M4 muscarinic acetylcholine receptor (mAChR), exhibiting an IC50 of 4.1 nM against the human M4 receptor. This compound demonstrates promise in the modulation of cholinergic signaling pathways, making it an invaluable tool for research on neuropharmacology and therapeutic interventions in disorders linked to M4 mAChR activity. Its oral bioavailability further supports its use in in vivo studies, aiding in the exploration of its potential effects on cognition and metabolic processes. -
Antiacetylcholine Compound
Oxyphenonium bromide is an antiacetylcholine compound that functions as a muscarinic acetylcholine receptor (mAChR) antagonist. It effectively mitigates bronchial obstruction by blocking acetylcholine's action, thereby reducing airway constriction. This compound is primarily utilized in research investigating respiratory conditions and the modulation of cholinergic signaling pathways. -
mAChR M1/3/5 PAM
VU0119498 is a positive allosteric modulator of muscarinic acetylcholine receptors M1, M3, and M5, showing EC50 values of 6.04 µM, 6.38 µM, and 4.08 µM, respectively. This compound exhibits significant antidiabetic activity, making it a valuable tool for studying metabolic disorders and receptor signaling pathways related to glucose homeostasis. Its modulation of mAChR activity provides insights into therapeutic strategies for diabetes and other related conditions. -
mAChR Inhibitor
Arborine is a potent mAChR inhibitor that modulates the peripheral actions of acetylcholine, leading to a significant reduction in blood pressure. This compound is particularly valuable in research applications focused on cardiovascular physiology and the mechanistic study of cholinergic signaling pathways. Its ability to influence blood pressure dynamics makes it an important tool for investigating therapeutic interventions in hypertension and related disorders. -
mAChR Antagonist
(±)-Darifenacin is a selective antagonist of the M3 muscarinic acetylcholine receptor (mAChR), functioning primarily by inhibiting receptor activation. This compound demonstrates potent activity in modulating smooth muscle contraction and glandular secretion, making it particularly useful for research in gastrointestinal disorders and urinary incontinence. Applications include studies on the mechanism of muscarinic receptor signaling and the development of therapeutic strategies targeting mAChR-related conditions. -
M4 mAChR Agonist
M4 mAChR agonist-1 is a selective agonist targeting the M4 muscarinic acetylcholine receptor. This compound exhibits potent activation of the M4 receptor with an EC50 greater than 10 μM in human cell systems. It is valuable for research applications focused on studying cholinergic signaling and neuropharmacology. -
mAChR M1 Antagonist
Cycrimine is an orally active antagonist of the muscarinic acetylcholine receptor M1, effectively inhibiting acetylcholine levels in models of Parkinson's disease. Its antispasmodic properties make Cycrimine a valuable tool for research in behavioral and mental disorders, providing insights into cholinergic signaling pathways. This compound is suitable for studies aimed at understanding the role of mAChRs in neurodegenerative conditions and related therapeutic interventions. -
mAChR 4 Antagonist
PCS1055 is a selective competitive antagonist of the muscarinic M4 receptor, exhibiting an IC50 of 18.1 nM and a Kd of 5.72 nM. It effectively inhibits radioligand [3H]-NMS binding to the M4 receptor with a Ki of 6.5 nM. Additionally, PCS1055 demonstrates inhibitory activity against acetylcholinesterase (AChE), with IC50 values of 22 nM for electric eel AChE and 120 nM for human AChE. This compound is valuable for research focused on muscarinic receptor signaling and cholinergic modulation. -
mAChR M2 Agonist
Arecaidine but-2-ynyl ester tosylate is a selective agonist of the mAChR M2 receptor, known to induce dose-dependent reductions in mean arterial pressure and heart rate in rodent models. This compound serves as a valuable tool in cardiovascular disease research, elucidating the role of mAChR M2 in cardiac function. Additionally, as a click chemistry reagent, Arecaidine but-2-ynyl ester tosylate contains an alkyne functional group, enabling its application in copper-catalyzed azide-alkyne cycloaddition reactions with azide-containing molecules for further synthetic applications. -
mAChR Agonist
Muscarine iodide is a potent agonist of the muscarinic acetylcholine receptors (mAChR). It actively stimulates the parasympathetic nervous system, making it a valuable tool in studying cholinergic signaling pathways. This compound is commonly utilized in research focused on neuropharmacology and the physiological effects of muscarinic receptor activation. -
mAChR Agonist
LASSBio-873 is a potent muscarinic acetylcholine receptor (mAChR) agonist that effectively crosses the blood-brain barrier. It exhibits significant analgesic properties in models of acute and inflammatory pain. Research indicates that the analgesic effects of LASSBio-873 can be antagonized by the M2 receptor inhibitor methoctramine, making it a valuable tool for studying pain mechanisms and mAChR signaling pathways. -
mAChR Antagonist
L-Hyoscyamine sulfate is a competitive antagonist of muscarinic acetylcholine receptors (mAChRs). This natural tropane alkaloid demonstrates significant biological activity by inhibiting mAChRs, making it useful in research applications focused on neuropharmacology and the modulation of cholinergic signaling. Its structural similarity to atropine further emphasizes its relevance in studies related to anticholinergic effects and the exploration of receptor interaction mechanisms. -
Anticholinergic Agent
Tridihexethyl chloride is an anticholinergic agent that acts as a muscarinic acetylcholine receptor (mAChR) antagonist. It exhibits significant antimuscarinic and antisecretory properties, providing pronounced antispasmodic effects on the gastrointestinal system. This compound is valuable for research related to peptic ulcer disease and acquired nystagmus, facilitating studies on gastrointestinal motility and secretion modulation. -
M4 mAChR Activator
Thiochrome is a selective enhancer of muscarinic acetylcholine receptor subtype M4. As a natural oxidation product and metabolite of thiamine, Thiochrome exhibits neutral cooperativity with acetylcholine at M1 to M3 receptors. This compound is valuable for studying the modulation of cholinergic signaling and its implications in neuropharmacology and therapeutic research. -
Stable Isotope
Tiotropium-d6 bromide is a deuterium-labeled analogue of Tiotropium, primarily targeting muscarinic acetylcholine receptors (mAChR). As a potent mAChR antagonist, it effectively inhibits the binding of acetylcholine, preventing the activation of ligand-gated ion channels. This reagent is valuable for studies involving receptor binding assays, pharmacokinetics, and metabolic pathway analysis.
